{"organizations": [], "uuid": "8e9577682e6251b991ad3c7aa1a6fbbf80a5562a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-anhui-anke-biotechnology-group-to/brief-anhui-anke-biotechnology-group-to-acquire-approval-for-clinical-trial-and-technique-of-monoclonal-antibody-injection-idUSL4N1PK4B2", "country": "US", "domain_rank": 408, "title": "BRIEF-Anhui Anke Biotechnology Group to acquire approval for clinical trial and technique of monoclonal antibody injection", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-25T20:20:00.000+02:00", "replies_count": 0, "uuid": "8e9577682e6251b991ad3c7aa1a6fbbf80a5562a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-anhui-anke-biotechnology-group-to/brief-anhui-anke-biotechnology-group-to-acquire-approval-for-clinical-trial-and-technique-of-monoclonal-antibody-injection-idUSL4N1PK4B2", "ord_in_thread": 0, "title": "BRIEF-Anhui Anke Biotechnology Group to acquire approval for clinical trial and technique of monoclonal antibody injection", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "anhui anke biotechnology group co ltd * says co", "sentiment": "negative"}, {"name": "brief-anhui anke biotechnology group", "sentiment": "negative"}, {"name": "jiangsu aosaikang pharmaceutical co ltd", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25(Reuters) - Anhui Anke Biotechnology Group Co Ltd\n* Says co plans to acquire approval for clinical trial and technique of a kind of monoclonal antibody injection from Jiangsu Aosaikang Pharmaceutical Co Ltd (seller), at the price of 50 million yuan\n* Say co also needs to pay sales commissions to seller\nSource text in Chinese: goo.gl/m4pD9h\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/m4pD9h"], "published": "2018-01-25T20:20:00.000+02:00", "crawled": "2018-01-26T21:20:04.004+02:00", "highlightTitle": ""}